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1. INTRODUCTION 
Drug delivery is the method of process of administering a pharmaceutical 
compound to achieve a therapeutic effect in humans or animals. Drug delivery 
technologies modify drug release profile, absorption, distribution and elimination for 
the benefit of improving product efficacy and safety, as well as patient covinenience 
and compliance. Drug release is from diffusion, degradation, swelling and affinity 
based mechanisms. Most common routes of administration include the preffered non- 
invasive peroral (through the mouth), topical (skin), transmucosal (nasal, buccal/ 
sublingual, vaginal, ocular and rectal) and inhalation routes. Many medications such 
as peptides and proteins, antibodies, vaccines and gene based drugs, in general may 
not be delivered using these routes because they might be susceptible to enzymatic 
degradation or cannot be absorbed in to the systemic circulation efficiently due to 
molecular size and charge issues to be therapeutically effective. For this reason many 
protein and peptide drugs have to be delivered by injection or a nanoneedle array. 
Current efforts in the area of drug delivery include the development of targeted 
delivery in which the drug is only active in the target area of the body and sustained 
release formulations in which the drug is released over a period of time in a controlled 
manner from a formulation.  
1.1  SUSTAINED RELEASE DOSAGE FORM: 1, 2 
 Sustained release dosage forms are designed to achieve a prolonged 
therapeutic effect by continuously releasing medication over extended period of after 
administration of a single dose. In case of injectable dosage forms, this period may 
vary from days to months. In the case of orally administrator forms, however this 
period is measured in hours and critically depends on residence time of the dosage 
formsin the gastro intestinal tract. The term “controlled release” has become 
associated with those systems from which therapeutic agents may be automatically 
delivered at pre defined rates over a long period of time. Products of this type have 
been formulated for oral, injectable and topical use and include inserts for  placement 
in the body cavities as well. 
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Fig  no 1: Drug level verses time profile showing differences between zero order, 
controlled release, slow first order sustained release and release from 
conventional tablet. 
 In general, the main aim of sustained release dosage form is to maintain the 
therapeutic blood level or tissue level of the drug for an extended period of time. This 
is usually accomplished by attempting to obtain zero order release from the dosage 
form. Zero order release constitutes of the amount of drug in the delivery system (i.e.; 
a constant release rate). Sustained release systems generally don’t attain this type of 
release and usually try to – zero order release by providing drug in a slow first order 
fashion (i.e.; concentration dependent). 
1.1.1. Rationale of sustained drug delivery: 3, 4  
The basic rationale for controlled drug delivery is to alter the pharmacokinetic 
and pharmacodynamics of pharmacologically active moieties by using novel drug 
delivery systems or by modifying the molecular structure and/or physiological 
parameters inherent in selected route of administration. It is desirable that the duration 
of drug action become more to design properly. Rate controlled dosage form, and less, 
or not at all, a property of the drug molecules inherent kinetic properties. 
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As mentioned earlier, primary objectives of controlled drug delivery are to ensure 
safety and to improve efficiency of drugs as well as patient compliance. This is 
achieved by better control of plasma drug levels and frequent dosing. For 
conventional dosage forms, only the dose (D) and dosing interval can vary and, for 
each drug, there exist a therapeutic window of plasma concentration, below which 
therapeutic effect is in sufficient, and above which toxic side effect are elicited. This is 
often defined as the ratio of median lethal dose (LD50) to median effective dose 
(ED50)  
1.1.2. Modified – release delivery systems: 
a. Delayed – release: 
                    It is used repetitive, intermitting dosing of a drug from one or more 
immediate release units incorporated into single dosage form. 
b. Sustained release: 
                       It includes any drug delivery systems that achieve slow release of drug 
over an extended period of time. If the systems can provide some control, whether this 
be of a temporal or spatial nature, or both of drug release in the body.  
c. Site specific targeting: 
                        It refer to targeting of a drug directly to a certain biological location. In 
case site specific release, the target is adjacent or in the diseased organ or tissue. 
d. Receptor targeting: 
                        The target is the particular receptor for a drug within an organ or tissue. 
 Advantages of sustained drug delivery: 
1. Avoid patient compliance problem. 
a) Employ less amount drug 
b) Minimize or eliminates local and systemic side effects. 
c) Obtain less protestations or deduction in drug activity with chronic use. 
d) Minimize drug accumulation with chronic dosing. 
 
Development and Evaluation of Sustained Release Bilayer Tablets of Carvedilol  
 
Dept. of Pharmaceutics, The Erode College of Pharmacy and Research Institute. Page 4 
 
2. Improve efficacy in treatment. 
a) Cure or controlled condition more promptly. 
b) Improve control of condition i.e.; reduce fluctuation in drug level. 
c)  Improve bioavailability of some drugs. 
d) Make use of special effects. 
 3. Economy. 
Disadvantages of sustained release dosage forms: 
a) Unpredictable and often poor in-vitro in vivo correlations, dose dumping, 
reduced potential for dosage adjustment and increased potential first pass 
clearance. 
b) They are more costly. 
c) Poor systemic availability in general. 
d) Effective drug release time period is influenced and limited by GI residence 
time. 
e) Need additional patient education. 
f) Dugs having very short half.  
1.1.3.Classification of oral sustained/controlled release systems: 5, 6 
A. Continous release systems 
1. Dissolution controlled release systems 
a) Matrix type             b) Reservoir type 
2. Diffusion controlled release systems  
        a) Matrix type             b) Reservoir type 
3. Dissolution and diffusion controlled release systems 
4. Ion exchange resins drug complexes 
5.  Slow dissolving salts and complexes 
6. pH dependent formulations 
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7. Osmotic pressure controlled systems 
8.Hydrodynamic pressure controlled systems 
B. Delayed transit and continuous release systems 
1. Altered density systems 
I. High density 
II. Low density 
III. Floating 
2. Mucoadhesive systems 
3. Size based systems 
C. Delayed released systems 
1. Intestinal release systems 
2. Colonic release systems 
1.1.4. Factors Affecting Sustained Release Dosage Forms: 7, 8 
Factors governing the design of sustained /controlled release dosage forms. 
A. Drug related factors 
1. Aqueous solubility 
2. Partition coefficient 
3. Molecular size 
4. Drug stability 
5. Protein binding 
B. Biological factors 
1. Absorption 
2. Distribution 
3. Elimination 
4. Duration of action 
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5. Margin of safety 
6. Side effects 
7. Disease state 
1.2. METHODS:9,10 
            Granulation is the act or process of forming or crystallizing into grains. 
Granules typically have a size range between 0.2 to 4.0 mm depending on their 
subsequent use.  
Synonym "Agglomeration": Agglomeration processes or in a more general 
term particle size enlargement technologies are great tools to modify product 
properties. Agglomeration of powders is widely used to improve physical properties 
like: wettability, flowability, bulk density and product appearance. 
            Granulation is carried out for various reasons, one of those is to prevent the 
segregation of the constituents of powder mix. Segregation is due to differences in the 
size or density of the component of the mix. Normally, the smaller and/or denser 
particles tend to concentrate at the base of the container with the larger and/or less 
dense ones on the top. An ideal granulation will contain all the constituents of the mix 
in the correct proportion in each granule and segregation of granules will not occur. 
Many powders, because of their small size, irregular shape or surface 
characteristics, are cohesive and do not flow well. Granules produced from such a 
cohesive system will be larger and more isodiametric, both factors contributing to 
improved flow properties. 
Some powders are difficult to compact even if a readily compactable adhesive is 
included in the mix, but granules of the same powders are often more easily 
compacted. This is associated with the distribution of the adhesive within the granule 
and is a function of the method employed to produce the granule. 
For example, if one were to make tablets from granulated sugar versus 
powdered sugar, powdered sugar would be difficult to compress into a tablet and 
granulated sugar would be easy to compress. Powdered sugar’s small particles have 
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poor flow and compression characteristics.These small particles would have to be 
compressed very slowly for a long period of time to make a worthwhile tablet. Unless 
the powdered sugar is granulated, it could not efficiently be made into a tablet that has 
good tablet characteristics such as uniform content or consistent hardness. 
1.2.1. Granulation techniques 
In pharmaceutical industry, two types of granulation technologies are employed, 
namely, Wet Granulation and Dry Granulation. 
Wet Granulation 
          Wet granulation, the process of adding a liquid solution to powders, is one of 
the most common ways to granulate. It involves the massing of a mix of dry primary 
powder particles using a granulating fluid. The fluid contains a solvent which must be 
volatile so that it can be removed by drying, and be non-toxic. Typical liquids include 
water, ethanol and isopropanol either alone or in combination. The liquid solution can 
be either aqueous based or solvent based. Aqueous solutions have the advantage of 
being safer to deal with than solvents. 
        Water mixed into the powders can form bonds between powder particles that are 
strong enough to lock them together. However, once the water dries, the powders may 
fall apart. Therefore, water may not be strong enough to create and hold a bond. In 
such instances, a liquid solution that includes a binder (pharmaceutical glue) is 
required. Povidone, which is a polyvinyl pyrrolidone (PVP), is one of the most 
commonly used pharmaceutical binders. PVP is dissolved in water or solvent and 
added to the process. When PVP and a solvent/water are mixed with powders, PVP 
forms a bond with the powders during the process, and the solvent/water evaporates 
(dries). Once the solvent/water has been dried and the powders have formed a more 
densely held mass, then the granulation is milled. This process results in the formation 
of granules. 
The process can be very simple or very complex depending on the 
characteristics of the powders, the final objective of tablet making, and the equipment 
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that is available. In the traditional wet granulation method the wet mass is forced 
through a sieve to produce wet granules which is subsequently dried. 
1.3. TABLETS:11,12 
 Solid medicaments may be administered orally in the form of powders, pills, 
cachets, capsules or tablet. These dosage forms contain a quantity of drug which is 
given as a single unit and they are known collectively as solid unit dosage forms, even 
in the case of sustained action preparations which, technically, contain the equivalent 
of several normal doses of drug.  
1.3.1. General properties of Tablet dosage forms:  
1. A tablet should have elegant product identity while free of defects like chips, 
cracks, discoloration, and contamination. 
2. Should have sufficient strength to withstand mechanical shock during its 
production packaging, shipping and dispensing.  
3. Should have the chemical and physical stability to maintain its physical 
attributes over time 
4. The tablet must be able to release the medicinal agents in a predictable and 
reproducible manner. 
5. Must have a chemical stability over time so as not to follow alteration of the 
medicinal agents. 
1.3.2. BILAYER SUSTAINED RELEASE TABLETS: 13, 14 
 Pharmaceutical products designed for oral delivery are mainly conventional 
drug delivery systems, which are designed for immediate release of drug for rapid 
absorption. These immediate release dosage forms have some limitations such as: 
1. Drugs with short half-life require frequent administration, which increases the 
chances of missing dose of drug leading to poor patient compliance. 
2. A typical peak-valley plasma concentration-time profile is obtained which 
makes difficult to attainment of steady state condition.  
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3. The unavoidable fluctuations in the drug concentration may lead to under 
medication or overmedication as the CSS values fall or rise beyond the 
therapeutic range.  
4. The fluctuating drug levels may lead to precipitation of adverse effects 
especially of a drug with small therapeutic index, whenever overmedication 
occurs.  
In order to overcome the drawbacks of conventional drug delivery systems, 
several technical advancements have led to the development of controlled and 
sustained drug delivery system. However despite of many advantages offered by oral 
sustained release dosage forms they have few disadvantages and Lag time is one of 
them. In order to achieve sustained therapeutic action oral SRDDS will release the 
drug at a slow rate and thus during the initial stages of medication, the plasma drug 
concentration generally stays below the minimum effective concentration and as a 
result the patient does not get any therapeutic benefit. 
Bilayer SR tablets are a solution to above problem. These preparations provide 
an immediate dose required for the normal therapeutic response, followed by the 
gradual release of drug in amounts sufficient to maintain the therapeutic response for a 
specific period of time. The major advantage of this category is that, in addition to the 
convenience of reduced frequency administration, it provides levels that are devoid of 
the peak and valley effect.  Bilayer tablets are novel drug delivery systems where 
combinations of two or more drugs in a single unit having different release profiles 
which improves patient compliance, prolong the drug action, avoid saw tooth kinetics 
resulting in effective therapy along with better control of plasma drug levels. 
Two layer tablets may be designed for sustained release-one for the immediate 
release of the drug and second layer for extended release thus maintaining prolonged 
blood level. Layers may be colour differently to identify the product the weight of 
each layer can be accurately controlled in contrast to putting one drug of a 
combination product in a sugar coating. 
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1.4. DISEASE PROFILE:15 
1.4.1. REVIEW OF CONGESTIVE HEART FAILURE: 
Congestive heart failure facts 
• Congestive heart failure (CHF) is a condition in which the heart's function as a 
pump is inadequate to meet the body's needs. 
• Many disease processes can impair the pumping efficiency of the heart to 
cause congestive heart failure. 
• The symptoms of congestive heart failure vary, but can include fatigue, 
diminished exercise capacity, shortness of breath, and swelling. 
• The diagnosis of congestive heart failure is based on knowledge of the 
individual's medical history, a careful physical examination, and selected 
laboratory tests. 
• The treatment of congestive heart failure can include lifestyle modifications, 
addressing potentially reversible factors, medications, heart transplant, and 
mechanical therapies. 
• The course of congestive heart failure in any given patient is extremely 
variable.  
Congestive heart failure 
Congestive heart failure (CHF) is a condition in which the heart's function as a 
pump is inadequate to deliver oxygen rich blood to the body. Congestive heart failure 
can be caused by: 
1. diseases that weaken the heart muscle, 
2. diseases that cause stiffening of the heart muscles, or  
3. diseases that increase oxygen demand by the body tissue beyond the 
capability of the heart to deliver adequate oxygen-rich blood. 
The heart has two atria (right atrium and left atrium) that make up the upper 
chambers of the heart, and two ventricles (left ventricle and right ventricle) that make 
up the lower chambers of the heart. The ventricles are muscular chambers that pump 
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blood when the muscles contract. The contraction of the ventricle muscles is called 
systole.  
Many diseases can impair the pumping action of the ventricles. For example, the 
muscles of the ventricles can be weakened by heart attacks, infections (myocarditis) or 
toxins (alcohol, some chemotherapy agents). The diminished pumping ability of the 
ventricles due to muscle weakening is called systolic dysfunction. After each 
ventricular contraction (systole) the ventricle muscles need to relax to allow blood 
from the atria to fill the ventricles. This relaxation of the ventricles is called diastole.  
Diseases such as hemochromatosis (iron overload) or amyloidosis can cause 
stiffening of the heart muscle and impair the ventricles' capacity to relax and fill; this 
is referred to as diastolic dysfunction. The most common cause of this is longstanding 
high blood pressure resulting in a thickened (hypertrophied) heart. Additionally, in 
some patients, although the pumping action and filling capacity of the heart may be 
normal, abnormally high oxygen demand by the body's tissues (for example, with 
hyperthyroidism or anemia) may make it difficult for the heart to supply an adequate 
blood flow (called high output heart failure). 
In some individuals one or more of these factors can be present to cause 
congestive heart failure. The remainder of this article will focus primarily on 
congestive heart failure that is due to heart muscle weakness, systolic dysfunction. 
Congestive heart failure can affect many organs of the body. For example: 
• The weakened heart muscles may not be able to supply enough 
blood to the kidneys, which then begin to lose their normal ability 
to excrete salt (sodium) and water. This diminished kidney function 
can cause the body to retain more fluid.  
• The lungs may become congested with fluid (pulmonary edema) 
and the person's ability to exercise is decreased.  
• Fluid may likewise accumulate in the liver, thereby impairing its 
ability to rid the body of toxins and produce essential proteins.  
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• The intestines may become less efficient in absorbing nutrients and 
medicines.  
• Fluid also may accumulate in the extremities, resulting in edema 
(swelling) of the ankles and feet.  
Eventually, untreated, worsening congestive heart failure will affect virtually every 
organ in the body. 
Causes of congestive heart failure 
Many disease processes can impair the pumping efficiency of the heart to cause 
congestive heart failure. In the United States, the most common causes of congestive 
heart failure are: 
• coronary artery disease 
• high blood pressure (hypertension)  
• longstanding alcohol abuse 
• disorders of the heart valves 
unknown (idiopathic) causes, such as after recovery from myocarditis 
Less common causes include viral infections of the stiffening of the heart 
muscle, thyroid disorders, disorders of the heart rhythm, and many others. 
It should also be noted that in patients with underlying heart disease, taking 
certain medications can lead to the development or worsening of congestive heart 
failure. This is especially true for those drugs that can cause sodium retention or affect 
the power of the heart muscle. Examples of such medications are the commonly used 
nonsteroidal anti-inflammatory drugs (NSAIDs), which include ibuprofen (Motrin and 
others) and naproxen (Aleve and others) as well as certain steroids, some medication 
for diabetes (such as rosiglitazone [Avandia] or pioglitazone [Actos]), and some 
calcium channel blockers. 
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Symptoms of congestive heart failure 
The symptoms of congestive heart failure vary among individuals according to the 
particular organ systems involved and depending on the degree to which the rest of the 
body has "compensated" for the heart muscle weakness.  
An early symptom of congestive heart failure is fatigue. While fatigue is a 
sensitive indicator of possible underlying congestive heart failure, it is 
obviously a nonspecific symptom that may be caused by many other 
conditions. The person's ability to exercise may also diminish. Patients may 
not even sense this decrease and they may subconsciously reduce their 
activities to accommodate this limitation. 
As the body becomes overloaded with fluid from congestive heart failure, 
swelling (edema) of the ankles and legs or abdomen may be noticed. This can 
be referred to as "right sided heart failure" as failure of the right sided heart 
chambers to pump venous blood to the lungs to acquire oxygen results in 
buildup of this fluid in gravity-dependent areas such as in the legs. The most 
common cause of this is longstanding failure of the left heart, which may lead 
to secondary failure of the right heart. Right-sided heart failure can also be 
caused by severe lung disease (referred to as "cor pulmonale"), or by intrinsic 
disease of the right heart muscle (less common)  
In addition, fluid may accumulate in the lungs, thereby causing shortness of 
breath, particularly during exercise and when lying flat. In some instances, 
patients are awakened at night, gasping for air.  
Some may be unable to sleep unless sitting upright.  
The extra fluid in the body may cause increased urination, particularly at night.  
Accumulation of fluid in the liver and intestines may cause nausea, abdominal 
pain, and decreased appetite. 
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Congestive heart failure diagnosed 
The diagnosis of congestive heart failure is most often a clinical one that is 
based on knowledge of the patient's pertinent medical history, a careful physical 
examination, and selected laboratory tests. 
A thorough patient history may disclose the presence of one or more of the 
symptoms of congestive heart failure described above. In addition, a history of 
significant coronary artery disease, prior heart attack, hypertension, diabetes, or 
significant alcohol use can be clues. 
The physical examination is focused on detecting the presence of extra fluid in the 
body (breath sounds, leg swelling, or neck veins) as well as carefully characterizing 
the condition of the heart (pulse, heart size, heart sounds, and murmurs). 
Useful diagnostic tests include the electrocardiogram (ECG) and chest X-ray 
to detect previous heart attacks, arrhythmia, heart enlargement, and fluid in and 
around the lungs. Perhaps the single most useful diagnostic test is the echocardiogram, 
in which ultrasound is used to image the heart muscle, valve structures, and blood 
flow patterns. The echocardiogram is very helpful in diagnosing heart muscle 
weakness. In addition, the test can suggest possible causes for the heart muscle 
weakness (for example, prior heart attack, and severe valve abnormalities). Virtually 
all patients in whom the diagnosis of congestive heart failure is suspected should 
ideally undergo echocardiography early in their assessment. 
Nuclear medicine studies assess the overall pumping capability of the heart 
and examine the possibility of inadequate blood flow to the heart muscle. Heart 
catheterization allows the arteries to the heart to be visualized with angiography (using 
dye inside of the blood vessels that can be seen using X-ray methods). During 
catheterization the pressures in and around the heart can be measured and the heart's 
performance assessed. In rare cases, a biopsy of the heart tissue may be recommended 
to diagnose specific diseases. This biopsy can often be accomplished through the use 
of a special catheter device that is inserted into a vein and maneuvered into the right 
side of the heart. 
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Another helpful diagnostic test is a blood test called a BNP or B-type 
natriuretic peptide level. This level can vary with age and gender but is typically 
elevated from heart failure and can aid in the diagnosis, and can be useful in following 
the response to treatment of congestive heart failure. 
The choice of tests depends on each patient's case and is based on the 
suspected diagnoses. 
Treatment of congestive heart failure 
Lifestyle modifications 
After congestive heart failure is diagnosed, treatment should be started 
immediately. Perhaps the most important and yet most neglected aspect of treatment 
involves lifestyle modifications. Sodium causes an increase in fluid accumulation in 
the body's tissues. Because the body is often congested with excess fluid, patients 
become very sensitive to the levels of intake of sodium and water. Restricting salt and 
fluid intake is often recommended because of the tendency of fluid to accumulate in 
the lungs and surrounding tissues. An American "no added salt" diet can still contain 4 
to 6 grams (4000 to 6000 milligrams) of sodium per day. In individuals with 
congestive heart failure, an intake of no more than 2 grams (2000 milligrams) of 
sodium per day is generally advised. Reading food labels and paying close attention to 
total sodium intake is very important. Severe restriction of alcohol consumption also 
is advised. 
Likewise, the total amount of fluid consumed must be regulated. Although 
many people with congestive heart failure take diuretics to aid in the elimination of 
excess fluid, the action of these medications can be overwhelmed by an excess intake 
of water and other fluids. The maxim that "drinking eight glasses of water a day is 
healthy" certainly does not apply to patients with congestive heart failure. In fact, 
patients with more advanced cases of congestive heart failure are often advised to 
limit their total daily fluid intake from all sources to 2 quarts. The above guidelines for 
sodium and fluid intake may vary depending on the severity of congestive heart 
failure in any given individual and should be discussed with their physician. 
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An important tool for monitoring an appropriate fluid balance is the frequent 
measurement of body weight. An early sign of fluid accumulation is an increase in 
body weight. This may occur even before shortness of breath or swelling in the legs 
and other body tissues (edema) is detected. A weight gain of two to three pounds over 
two to three days should prompt a call to the physician, who may order an increase in 
the dose of diuretics or other methods designed to stop the early stages of fluid 
accumulation before it becomes more severe. 
Aerobic exercise, once discouraged for congestive heart failure patients, has 
been shown to be beneficial in maintaining overall functional capacity, quality of life, 
and perhaps even improving survival. Each person's body has its own unique ability to 
compensate for the failing heart. Given the same degree of heart muscle weakness, 
individuals may display widely varying degrees of limitation of function. Regular 
exercise, when tailored to the person's tolerance level, appears to provide significant 
benefits and should be used only when the individual is compensated and stable. 
1.4.2. REVIEW OF HYPERTENSION:16 
Hypertension (HTN) or High Blood Pressure is a cardiac chronic medical 
condition in which the systemic arterial blood pressure is elevated. It is the opposite of 
hypotension. Hypertension is classified as either primary (essential) hypertension or 
secondary hypertension; About 90–95% of cases are categorized as "primary 
hypertension," which means high blood pressure with no obvious medical cause. The 
remaining 5–10% of cases (Secondary hypertension) are caused by other conditions 
that affect the kidneys, arteries, heart or endocrine system.  
  Persistent hypertension is one of the risk factors for stroke, myocardial 
infarction, heart failure and arterial aneurysm, and is a leading cause of chronic kidney 
failure. Moderate elevation of arterial blood pressure leads to shortened life 
expectancy. Dietary and lifestyle changes can improve blood pressure control and 
decrease the risk of associated health complications, although drug treatment may 
prove necessary in patients for whom lifestyle changes prove ineffective or    
insufficient.  
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Classification 
 
        
 
The variation in pressure in the left ventricle (blue line) and the aorta (red line) over 
two cardiac cycles ("heart beats"), showing the definitions of systolic and diastolic 
pressure. 
 
 
 
Classification 
Systolic pressure Diastolic pressure 
mmHg  kPa  mmHg kPa 
Normal 90–119 12–15.9 60–79 8.0–10.5 
Prehypertension 120–139 16.0–18.5 80–89 10.7–11.9 
Stage 1 140–159 18.7–21.2 90–99 12.0–13.2 
Stage 2 ≥160 ≥21.3 ≥100 ≥13.3 
Isolated systolic 
hypertension 
≥140 ≥18.7 <90 <12.0 
Blood pressure is usually classified based on the systolic and diastolic blood 
pressures. Systolic blood pressure is the blood pressure in vessels during a heart beat. 
Diastolic blood pressure is the pressure between heartbeats. A systolic or the diastolic 
blood pressure measurement higher than the accepted normal values for the age of the 
individual is classified as prehypertension or hypertension. 
Hypertension  has several sub-classifications, including hypertension stage I, 
hypertension stage II, and isolated systolic hypertension. Isolated systolic 
hypertension refers to elevated systolic pressure with normal diastolic pressure and is 
common in the elderly. These classifications are made after averaging a patient's 
resting blood pressure readings taken on two or more office visits. Individuals older 
than 50 years are classified as having hypertension if their blood pressure is 
consistently at least 140 mmHg systolic or 90 mmHg diastolic. Patients with blood 
pressures higher than 130/80 mmHg with concomitant presence of diabetes mellitus or 
kidney disease require further treatment.  
Hypertension is also classified as resistant if medications do not reduce blood 
pressure to normal levels.  
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Exercise hypertension is an excessively high elevation in blood pressure 
during exercise. The range considered normal for systolic values during exercise is 
individual is at risk for developing hypertension at rest.   
 
 Signs and Symptoms 
      Mild to moderate essential hypertension is usually asymptomatic.  
Accelerated Hypertension 
Accelerated hypertension is associated with headache, drowsiness, confusion, 
vision disorders, nausea, and vomiting. These symptoms are collectively called 
hypertensive encephalopathy. Hypertensive encephalopathy is caused by severe small 
blood vessel congestion and brain swelling, which is reversible if blood pressure is 
lowered.  
Secondary Hypertension 
Some additional signs and symptoms suggest that the hypertension is caused 
by disorders in hormone regulation. Hypertension combined with obesity distributed 
on the trunk of the body, accumulated fat on the back of the neck ('buffalo hump'), 
wide purple marks on the abdomen (abdominal striae), or the recent onset of diabetes 
suggests that an individual has a hormone disorder known as Cushing's syndrome. 
Hypertension caused by other hormone disorders such as hyperthyroidism, 
hypothyroidism, or growth hormone excess will be accompanied by additional 
symptoms specific to these disorders. For example, hyperthyrodism can cause weight 
loss, tremors, heart rate abnormalities, reddening of the palms, and increased 
sweating. Signs and symptoms associated with growth hormone excess include 
coarsening of facial features, protrusion of the lower jaw, enlargement of the tongue, 
excessive hair growth, darkening of the skin color, and excessive sweating. Other 
hormone disorders like hyperaldosteronism may cause less specific symptoms such as 
numbness, excessive urination, excessive sweating, electrolyte imbalances and 
dehydration, and elevated blood alkalinity. and also cause mental pressure. 
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In pregnancy 
Hypertension in pregnant women is one symptom of pre-eclampsia. Pre-
eclampsia can progress to a life-threatening condition called eclampsia, which is the 
development of protein in the urine, generalized swelling, and severe seizures. Other 
symptoms indicating that brain function is becoming impaired may precede these 
seizures such as nausea, vomiting, headaches, and vision loss.  
In addition, the systemic vascular resistance and blood pressure decrease 
during pregnancy. The body must compensate by increasing cardiac output and blood 
volume to provide sufficient circulation in the utero-placental arterial bed.  
 
In Children 
Some signs and symptoms are especially important in newborns and infants 
such as failure to thrive, seizures, irritability, lack of energy, and difficulty breathing. 
In children, hypertension can cause headache, fatigue, blurred vision, nosebleeds, and 
facial paralysis.  
Even with the above clinical symptoms, the true incidence of pediatric 
hypertension is not known. In adults, hypertension has been defined due to the adverse 
effects caused by hypertension. However, in children, similar studies have not been 
performed thoroughly to link any adverse effects with the increase in blood pressure. 
Therefore, the prevalence of pediatric hypertension remains unknown due to the lack 
of scientific knowledge. 
CAUSE 
 Essential Hypertension 
          Essential hypertension is the most prevalent hypertension type, affecting 90–
95% of hypertensive patients. Although no direct cause has been identified, there are 
many factors such as sedentary lifestyle, smoking, stress, visceral obesity, potassium 
deficiency (hypokalemia), obesity (more than 85% of cases occur in those with a body 
Development and Evaluation of Sustained Release Bilayer Tablets of Carvedilol  
 
Dept. of Pharmaceutics, The Erode College of Pharmacy and Research Institute. Page 20 
 
mass index greater than 25), salt (sodium) sensitivity, alcohol intake, and vitamin D 
deficiency that increase the risk of developing hypertension. Risk also increases with 
aging, some inherited genetic mutations, and having a family history of hypertension. 
An elevated level of renin, a hormone secreted by the kidney, is another risk factor, as 
is sympathetic nervous system overactivity. Insulin resistance, which is a component 
of syndrome X (or the metabolic syndrome), is also thought to contribute to 
hypertension. Recent studies have implicated low birth weight as a risk factor for adult 
essential hypertension.  
Secondary Hypertension 
        Secondary hypertension by definition results from an identifiable cause. This 
type is important to recognize since it's treated differently to essential hypertension, by 
treating the underlying cause of the elevated blood pressure. Hypertension results in 
the compromise or imbalance of the pathophysiological mechanisms, such as the 
hormone-regulating endocrine system, that regulate blood plasma volume and heart 
function. Many conditions cause hypertension. Some are common, well-recognized 
secondary causes such as renovascular hypertension and Cushing's syndrome, which 
is a condition where the adrenal glands overproduce the hormone cortisol. 
Hypertension is also caused by other conditions that cause hormone changes, such as 
hyperthyroidism, hypothyroidism (citation needed), and certain tumors of the adrenal 
medulla (e.g., pheochromocytoma). Other common causes of secondary hypertension 
include kidney disease, obesity/metabolic disorder, pre-eclampsia during pregnancy, 
the congenital defect known as coarctation of the aorta, and certain prescription and 
illegal drugs. 
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It is also known that hypertension is highly heritable and polygenic (caused by 
more than one gene) and a few candidate genes have been postulated in the etiology of 
this condition.  
Recently, work related to the association between essential hypertension and 
sustained endothelial damage has gained popularity among hypertension scientists. It 
remains unclear, however, whether endothelial changes precede the development of 
hypertension or whether such changes are mainly due to longstanding elevated blood 
pressures. 
Diagnosis 
Hypertension is generally diagnosed on the basis of a persistently high blood 
pressure. Usually this requires three separate sphygmomanometer measurements at 
least one week apart. Diagnosis often entails three separate visits to the physician's 
office. Initial assessment of the hypertensive patient should include a complete history 
and physical examination. Exceptionally, if the elevation is extreme, or if symptoms 
of organ damage are present, then a diagnosis may be made and treatment started 
immediately. 
Once the diagnosis of hypertension has been made, physicians will attempt to 
identify the underlying cause based on risk factors and other symptoms, if present. 
Secondary hypertension is more common in preadolescent children, with most cases 
caused by renal disease. Primary or essential hypertension is more common in 
adolescents and has multiple risk factors, including obesity and a family history of 
hypertension. Laboratory tests can also be performed to identify possible causes of 
secondary hypertension, and to determine whether hypertension has caused damage to 
the heart, eyes, and kidneys. Additional tests for diabetes and high cholesterol levels 
are usually performed because these conditions are additional risk factors for the 
development of heart disease and require treatment. 
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Prevention 
The degree to which hypertension can be prevented depends on a number of 
features including current blood pressure level, sodium/potassium balance, detection 
and omission of environmental toxins, changes in end/target organs (retina, kidney, 
heart, among others), risk factors for cardiovascular diseases and the age at diagnosis 
of prehypertension or at risk for hypertension. A prolonged assessment that involves 
repeated blood pressure measurements provides the most accurate blood pressure level 
assessment. Following this, lifestyle changes are recommended to lower blood 
pressure, before the initiation of prescription drug therapy. The process of managing 
prehypertension according the guidelines of the British Hypertension Society suggest 
the following lifestyle changes: 
• Weight reduction and regular aerobic exercise (e.g., walking): Regular 
exercise improves blood flow and helps to reduce the resting heart rate 
and blood pressure.  
• Reduce dietary sugar 
• Reduce sodium (salt) in the body by disuse of condiment sodium and 
the adoption of a high potassium diet which rids the renal system of 
excess sodium. Many people use potassium chloride salt substitute to 
reduce their salt intake.  
Additional dietary changes beneficial to reducing blood pressure include the 
DASH diet (dietary approaches to stop hypertension) which is rich in fruits 
and vegetables and low-fat or fat-free dairy products. Research sponsored by 
the National Heart, Lung, and Blood Institute. showed this diet to be effective. 
In addition, an increase in dietary potassium, which offsets the effect of 
sodium has been shown highly effective in reducing blood pressure.  
Discontinuing tobacco use and alcohol consumption has been shown to lower 
blood pressure. The exact mechanisms are not fully understood, but blood 
pressure (especially systolic) always transiently increases following alcohol or 
nicotine consumption. Abstaining from cigarette smoking reduces the risks of 
stroke and heart attack associated with hypertension.  
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Vasodialators such as niacin. 
Limiting alcohol intake to less than 2 standard drinks per day can reduce 
systolic blood pressure by between 2-4mmHg.  
Reducing stress, for example with relaxation therapy, such as meditation and 
other mindbody relaxation techniques,by reducing environmental stress such 
as high sound levels and over-illumination can also lower blood pressure. 
Jacobson's Progressive Muscle Relaxation and biofeedback are also beneficial, 
such as device-guided paced breathing,although meta-analysis suggests it is 
not effective unless combined with other relaxation techniques.  
Increasing omega 3 fatty acids can help lower hypertension. Fish oil is shown 
to lower blood pressure in hypertensive individuals. The fish oil may increase 
sodium and water excretion.  
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2.LITERATURE REVIEW 
Sonia Pandey et al, (2010) Carvedilol was formulated as a bilayered buccal tablet in 
order to avoid the first-pass effect and decrease the drug loss using different polymers 
and excipients. Eight formulations were made using different ratio of carbopol 934P 
and HPMC K4M.The formulations were tested for in vitro drug release, in vitro 
bioadhesion, moisture absorption and in vitro drug permeation through porcine buccal 
mucosa. The dissolution of Carvedilol from all the prepared tablets into phosphate 
buffer (pH 6.8) was controlled and followed by non-fickian release mechanism. 
Dissolution studies of the tablets of optimized batch containing 5% Carbopol 
934P/65% HPMC K4M/30% lactose showed 82.7% release of drug in 6 h. The 
mucoadhesive strength and residence time of the optimized batch are 17.93 g and 9.45 
h respectively. The swelling index and microenvironment pH of the optimized batch 
after 6 h are 77.54 and 6.76 respectively. Procured sample of carvedilol was tested for 
its identification by taking FTIR of pure drug. Drug excipient compatibility was done 
at 30°C ,65% ± 5%RH, and 40°C 75% ± 5%RH using open and closed vial for four 
weeks and observed for physical changes.  
Ziyaur Rahman et al, (2006) Investigated was to develop a bilayer floating tablet 
(BFT) for captopril using direct compression technology. HPMC K-grade and 
effervescent mixture of citric acid and sodium bicarbonate formed the floating layer. 
The release layer contained captopril and various polymers such as HPMC-K15M, 
PVP-K30 and Carbopol 934p, alone or in combination with the drug. The floating 
behaviour and in vitro dissolution studies were carried out in a USP 23 apparatus 2 in 
simulated gastric fluid (without enzyme, pH 1.2). Final formulation released 
approximately 95% drug in 24 h in vitro, while the floating lag time was 10 min and 
the tablet remained floatable throughout all studies. Final formulation followed the 
Higuchi release model and showed no significant change in physical appearance, drug 
content, floatability or in vitro dissolution pattern after storage at 45 °C/75% RH for 
three months.  
 Swamy P.V. et al, (2011)  Design and evaluate bilayer buccal tablets of granisetron 
hydrochloride (an anti-emetic drug), in order to overcome bioavailability problems, to 
reduce dose dependent side effects and frequency of administration. Bilayer buccal 
tablets containing the drug were prepared by direct compression method using 
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combination of polymers (such as sodium alginate, HPMC 50 cps and Carbopol 934p) 
and ethyl cellulose as an impermeable backing layer to release the drug in a 
unidirectional way toward the mucosa, thus avoiding loss of drug due to wash out by 
saliva. The designed tablets were evaluated for various physical and biological 
parameters, drug content uniformity, in-vitro drug release, short-term stability, drug- 
excipient interactions (FTIR). The formulation SAF with the drug matrix layer 1 
composition- sodium alginate (47% w/w), Carbopol 934p (3% w/w), PVP K-30 
(binder, 30% w/w) and mannitol (channeling agent, 15% w/w) was found to be 
promising. This optimized formulation exhibited an in vitro drug release of 94% in 8 h 
along with satisfactory bioadhesion strength (4.6 gm).Short-term stability studies 
(40±2 C/75±5% RH for 3 months) 
 
N.G.Raghavendra Rao  et al, (2010)   Develop controlled zero‐order release 
glipizide bilayered matrix tablets using different grades of hydroxy propyl methyl 
cellulose (HPMC) as novel release modifier along with xanthan gum (XG), guar gum 
(GG), and karaya gum (KG) as release retardants. Bilayered matrix tablets of glipizide 
were prepared by wet granulation method. The release rate were modulated by 
varying concentration of different types of rate controlling material as well as in a 
combination of two different rate controlling material. After evaluation of physical 
properties of tablets, the in vitro release study was performed in phosphate buffer pH 
7.4 upto 12 hrs. The effect of polymer concentration and polymer blend concentration 
were studied. All precompressional parameters were found to be within acceptable 
standard limits. It was observed that bilayer matrix tablets contained polymer blend of 
HPMC/Ethyl cellulose were successfully sustained the release of drug upto 12 hrs. 
The release data were fit into 
different kinetic models (zero order, first order and Korsemeyer‐Peppas powers law 
equation). The DSC and FTIR studies demonstrated that there was no interaction 
between polymers and drug. Stability studies were carried out according ICH 
guidelines. Stability studies (40±2oC/75±5% RH) for 6 months indicated that 
glipizide was stable in matrix tablets. 
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N.N.Rajendran et al, (2011)   Establish Bi‐layer tablets containing Metformin HCl as 
sustained release and Pioglitazone HCl as immediate release layer.Sustained layer 
were prepared by wet granulation method using different viscosity grade of HPMC 
(HPMC K4M & HPMC K100M) as polymers and immediate release layer were 
prepared by direct compression method using superdisintegrants such as sodium 
starch glycolate and crosscarmellose sodium. The tablets were evaluated for 
physicochemical properties. All the values were found to be within limit. In vitro 
release studies were carried out by USP type‐2 paddle apparatus. The result showed 
that combinations of polymers namely HPMC K100M and HPMC K4M in sustained 
layer can control the release of drug. The in vitro release profiles of drug from 
sustained release layer could be best expressed by Higuchi’s equation as the plots 
showed high linearity (R2 >0.988) and diffusion was the dominant mechanism of drug 
release. The formulations (P6M7) having immediate release layer produces immediate 
effect within 54 second followed by sustained release (97.35%) at 8 hrs and it 
comparable with innovator. 
 
Anilkumar J. Shinde et al, (2010)  Investigation was to prepared a gastroretentive 
floating drug delivery system (GFDDS) of cephalexin( CFL). Sustained release of 
floating tablets of cephalexin were formulated employing the hydrophilic polymer 
hydroxy propyl methyl cellulose (HPMC), gas generating agent sodium bicarbonate 
and citric acid. A 32 factorial design was applied systematically; the amount of citric 
acid (X1) and amount of HPMC K100M (X2) were selected as independent variables. 
The time required for 50% drug release (t50%), percentage drug release at 12 hours 
(Q12) and percentage drug release at 6 hours (Q6) were selected as dependent 
variables. The results of factorial design indicated that high level of HPMC K100M 
and citric acid favors preparation of floating sustained release tablet of cephalexin. 
The granules were prepared by wet granulation method and evaluated for their 
granules properties. 
 
R.Nagaraju et al, (2009)  Salbutamol and theophylline are available in conventional 
dosage forms, administered four times a day,leading to saw tooth kinetics and 
resulting in ineffective therapy. The combination of these two drugs in a single dosage 
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form will enhance the patient compliance and prolong bronchodilation. Various 
polymers, such as hydroxy propyl methylcellulose K4M (HPMC- K4M), hydroxy 
propyl methylcellulose K100M (HPMC- K100M), xanthan gum, ethyl cellulose and 
hydroxy propyl methylcellulose phthalate (HPMC-P) were studied. HPMC-P and 
HPMC- K4M were found to be best in controlling the release. In-vitro dissolution 
studies were carried out for all the bi-layered tablets developed using USP dissolution 
apparatus type 2 (paddle). It was found that the tablet FB15-FW3 showed 50% release 
of salbutamol in first hour and the remaining was released for eight hours. However, 
theophylline was found to be released as per the USP specifications. The IR spectrum 
was taken for FB15-FW3 formulation and it revealed that there is no disturbance in 
the principal peaks of pure drugs salbutamol and theophylline.  
 
B.Vijaya Kumar et al, (2010)      Develop a Bilayer tablet of guaifenesin (GBT) 
using superdisintegrant MCC and sodium starch glycolate for the fast release layer 
and metalose 90 SH and carbopol 934 for the sustaining layer. In vitro dissolution 
studies were carried out in a USP 24 apparatus I. The formulations gave an initial 
burst effect to provide the loading dose of the drug followed by sustained release for 
12 h from the sustaining layer of matrix embedded tablets. In vitro dissolution kinetics 
followed the Higuchi model via a non-Fickian diffusion controlled release mechanism 
after the initial burst release. Stability studies conducted for optimized formulation did 
not show any change in physical appearance, drug content, matrix integrity and in 
vitro drug release.  
 
Chinam Niranjan Patra et al, (2007)    Develop a bilayer tablet of propranolol 
hydrochloride using superdisintegrant sodium starch glycolate for the fast release 
layer and water immiscible polymers such as ethylcellulose, Eudragit RLPO and 
Eudragit RSPO for the sustaining layer. In vitro dissolution studies were carried out in 
a USP 24 apparatus I. The formulations gave an initial burst effect to provide the 
loading dose of the drug followed by sustained release for 12 h from the sustaining 
layer of matrix embedded tablets. In vitro dissolution kinetics followed the Higuchi 
model via a non-Fickian diffusion controlledrelease mechanism after the initial burst 
release. FT-IR studies revealed that there was no interaction between the drug and 
polymers used in the study. Statistical analysis (ANOVA) showed no significant 
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difference in the cumulative amount of drug release after 15 min, but significant 
difference (p < 0.05) in the amount of drug released after 12 h from optimized 
formulations was observed. 
 
SH Lakade et al, (2008)   Develop hydrophilic polymer (HPMC) and hydrophobic 
polymer (Ethyl cellulose) based Nicorandil matrix sustained release tablet which can 
release the drug up to time of 24 hrs in predetermined rate. The formulation of 
Nicorandil matrix tablet was prepared by the polymer combination in order to get 
required theoretical release profile. The influence of hydrophilic and hydrophobic 
polymer and granulation technique on Nicorandil was studied. The formulated tablet 
were also characterized by physical and chemical parameters, The in-vitro release rate 
profile should the higher concentration of F2 polymer in tablet, the combination of 
hydrophilic and hydrophobic combination showed less result than use of alone. The 
in–vitro release data was well fit to Peppas and Hixon crowel release kinetics. 
 
MR.Ashish A Pahade et al, (2010)  Develop bilayer sustained release tablet of 
Isosorbide mononitrate, an anti-anginal organic nitrate vasodilator. The tablets were 
prepared by wet granulation method. Hydrophilic and hydrophobic matrix materials 
such as hydroxypropyl methylcellulose, and polyox were used, which can release the 
drug up to 24hrs in predetermined rate. Binder used was pvp k-30. The influence of 
hydrophilic and hydrophobic polymer and granulation technique was studied. 
 
 P.Dinesh Kumar et al, (2010) Prepare a bilayer gastro retentive tablet of ranitidine 
using direct compression technology and optimize the type and concentration of 
polymer to give maximum retentive effect with good drug release profile. Ranitidine 
H
2 
receptor antagonist having short biological half life (2-3.5 h), absorption in the 
initial part of the small intestine and 50% absolute bioavailability of drug favor 
development of sustained release floating formulation. In this study, a bilayer tablet 
was prepared which contains an immediate release portion and a floating layer. 
HPMC-K-100, HPMC-K-4M, HPMC-E-15, CARBOPOL-934 were used as gel 
forming agents either alone or in combination. Sodium bicarbonate, and citric acid as 
gas generating agent, lactose as additive combine with the polymer to form the 
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floating layer
1
. The bilayer tablets were characterized by lag time, floating time, 
weight variation, drug content and dissolution profile. Best Formulation BLF6 
[HPMC-K100 (1:1)] shows lag time of 25 s, floating time of 24 h and drug release of 
99.85%. The best formulation was taken up for animal studies as approved by 
Institutional Animal Ethical Committee. The X-ray studies for floating properties of 
tablet and the in vivo bioavailability studies for the formulation was carried out using 
rabbits which showed a significant increase in bioavailability of drug as compared 
with conventional dosage forms. The optimized formulation was subjected to stability 
studies at 40 ± 2
0 
and 75 ± 5% RH for period of three months. 
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                             3.DRUG PROFILE 
Carvedilol:17 
Description           : It is a non – selective beta blocker; it blocks β-1 and β-2 
adrenergic receptors as well as the α-1 adrenergic receptors. It is a white or almost  
white, crystalline powder.  
Chemical Name      : (2RS)-1-(9 H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)  
                              ethyl] amino]propan-2-ol 
Chemical Structure: 
 
Molecular Formula : C24H26N2O4 
Molecular Weight : 406.5 g/mole 
Melting point      : 114 - 1150C. 
Solubility   : It is easily soluble in dimethyl sulfoxide (DMSO), 
also easily soluble in methanol and methelene 
chloride, isopropranolol, ethyl ether and ethanol can 
partially dissolve. Practically insoluble in water. 
Dose : 25mg twice a day in the treatment of congestive heart 
failure. 
 
Elimination half life          : 6 - 8 hours 
Bioavailability                  : 25 - 35%  
3.1.PHRMACOKINETICS:18                                                                      
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Absorption 
i.) Non-genetic 
a. Food: decreases rate (not extent) of absorption 
b. Age: 50% increase in bioavailability in elderly (increased plasma 
concentrations) 
c. Liver disease: oral bioavailability significantly increased 
d. Concomitant medications/substances: p-glycoprotein inhibitors 
ii.) Genetic 
a.  Genetic variation in p-glycoprotein gene   
Distribution 
i.) Non-genetic 
a. Liver disease: 4-fold increase in volume of distribution 
b. Altered serum protein (>95% protein bound, primarily to albumin) 
c. Concomitant medications/substances: p-glycoprotein inhibitors or      
activators 
ii.) Genetic 
 a. Genetic variation in p-glycoprotein gene 
Metabolism 
 I) Non-genetic 
a. Congestive heart failure (CHF): 30-40% higher plasma concentrations 
b. Liver impairment 
i. 4- to 7-fold higher concentrations in cirrhotic liver disease 
ii. Contraindicated in severe hepatic impairment 
c. Concomitant medications/substances: CYP2C9, CYP2D6, CYP3A4, 
CYP2C19, CYP1A2, CYP2E1inducers or inhibitors 
II) Genetic 
a. Genetic variation in drug metabolizing enzyme gene(s): CYP2C9, CYP2D6, 
CYP3A4, CYP2C19, CYP1A2, CYP2E1 
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Excretion 
i.) Non-genetic 
a.Renal impairment: increased plasma concentrations 
b. Renal impairment + hypertension: markedly increased plasma 
concentrations 
c. 50% shorter elimination half-life in pediatrics (ages 6 weeks – 19 years) 
with CHF 
d. Age: Elimination half-life increases with age in pediatrics 
ii.) Genetic 
a. No clear genetic factors affecting excretion. 
3.2. PHRMACODYNAMICS: 
  Receptors 
     i.) Non-genetic 
 a. Concomitant medications: alpha- or beta-adrenergic receptor 
agonists/antagonists    (may block or enhance therapeutic effects of carvedilol) 
   ii.) Genetic 
 a. Genetic variation in beta-1 adrenergic receptor gene 
 b. Genetic variation in alpha-1 adrenergic receptor gene 
 c. Genetic variation in Gs protein alpha subunit gene 
Transporters 
   i.) Non-genetic 
           Concomitant medications/substances: p-glycoprotein inhibitors or activators. 
   ii.) Genetic 
           Genetic variation in p-glycoprotein gene. 
3.3. SIDE EFFECTS AND PRECAUTIONS: 
Dizziness, Edema (fluid accumulation), decreased heart rate, diarrhea, postural 
hypotension, irregular heart rhythm, abnormalities of vision.  
Carvedilol should be used cautiously in patients who use diuretics or who are elderly 
or have cirrohosis, asthma, peripheral vascular disease, hyperthyroidism, variant 
angina and kidney disease. 
3.4. CONTRAINDICATIONS:  
 It is contraindicated during pregnancy. 
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4.1. ETHYLCELLULOSE: 
Description: 
 Ethyl cellulose is a tasteless, free
Chemical Name:  
  Cellulose ethyl ether.
Chemical Structure: 
                                             
 
 
 
 
 
 
Functional Category :  
Coating agent, flavoring fixativ
 Viscosity : 
increasing agent. 
Solubility:  
Soluble in chloroform, ethanol (95%), ethyl acetate, methanol, and
Practically insoluble in glycerin, propylene glycol
Bulk density   
Viscosity   
Specific gravity  
Stability:  
Pharmacy and Research Institute.
4. POLYMER PROFILE 
19, 20
  
-flowing, white to light tan colored 
 
 
e, tablet binder, tablet filler.  
 and water.                                      
: 0.4 g/cm3 
: 7 to 100 mPa s for 5% w/v solutions
: 1.12–1.15 g/cm3 
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   powder. 
 toluene. 
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Ethyl cellulose is a stable, slightly hygroscopic material chemically resistant to 
alkalis (both dilute and concentrated) and to salt solutions, although it is more 
sensitive to acidic materials than are cellulose esters. 
Incompatibility:  
Incompatible with paraffin wax and microcrystalline wax. 
Application:  
1) The main use of ethyl cellulose in oral formulations is as a hydrophobic 
coating agent for tablets and granules. 
2) Ethyl cellulose coatings are used to modify the release of a drug, to mask an 
unpleasant taste, or to improve the stability of a formulation; for example, where 
granules are coated with ethyl cellulose to inhibit oxidation. 
3) Modified-release tablet formulations may also be produced using ethyl 
cellulose as a matrix former 
Safety:  
Ethyl cellulose is widely used in oral and topical Pharmaceutical formulations. 
It is also used in food products. 
4.2. EUDRAGIT RSPO: 21 
Synonyms:  
Polymeric methacrylates. 
Description:  
Fine white powder with slightly amine-like odor. 
Chemical Name:  
Poly (ethylacrylate,methyl methacrylate) trimethyl ammonio ethyl 
methacrylate chloride.  
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Chemical Structure: 
 
 
 
 
 
Functional category 
Behavior in Digestive 
Juices 
Bulk Density 
True Density 
Marketed forms 
Flash point     
Solubility: 
 Soluble in acetone, alcohol, dichloromethane, ethyl acetate, insoluble in water 
and petroleum ether.  
Stability and Storage:  
Dry powder polymer forms are stable at temperatures less than 30°C and 
should be stored in a tightly closed container at less than
 
 
Pharmacy and Research Institute.
  
: Film former, Tablet binders, Tablet diluents, 
sustained release polymer.  
: Insoluble film of low permeability. 
: 0.390 g/cm3 
: 0.816 - 0.836 g/cm3 
: Powder 
: Not inflammable. 
 30°C. 
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Applications :  
Eudragit is employed as a coating material, usually for coating  pellets or 
micro particles that are filled in to capsules or compressed into tablets. Eudragit RS 
has been used as a sustained release coating material. Water can penetrate in the 
Eudragit RS material and dissolve the encapsulated material, which then diffuses in 
the aqueous phase and finally into bulk solution. Eudragit serves as a matrix in which 
the active is embedded. The matrix structure is obtained by direct compression and 
wet granulation. Eudragit may additionally be used to form the matrix layers of 
transdermal delivery system. They have also been used to prepare novel gel 
formulation for rectal administration. 
 
4.3. HYDROXY PROPYL METHYL CELLULOSE 4000: 22 
Non Proprietary Name:  
     BP  : Hypermellose 
     PhEur : Methylhydroxypropylcellulosum 
     USP  : Hydroxypropyl methyl cellulose 
Synonyms:  
Cellulose, hydroxypropyl methyl ether, methocel, ethylcellulose propylene 
glycol ether, methyl hydroxyl propylcellulo metolose, pharmacoat. 
Description:  
Hydroxypropyl methylcellulose is an odourless and tasteless                                          
white or creamy white coloured fibrous or granular powder. 
Chemical Name:  
Cellulose, 2-Hydroxypropyl methyl ether. 
Functional Category:  
Coating agent, film former, stabilizing agent, suspending agent, tablet binder, 
viscosity increasing agent. 
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Empirical Formula:  
The Ph Eur describes HPMC as a partly O-methylated and o-(2-
hydroxypropylated) cellulose. It is available in several grades which vary in viscosity 
and extent of substitution. HPMC defined in the USP XXII specifies the substitution 
type by appending a four digit number to the non      proprietary name, e.g., 
hydroxypropyl methylcellulose 1828. The first two digits refer to the approximate 
percentage content of the methoxy group (OCH3). The      second two digits refer to 
the approximate percentage content of the hydropropoxy group (OCH2CHOHCH3). 
Tapped Density : 0.05-0.70g/cm3 for pharmacoat. 
Melting Point  : Browns at 190-2000C, chars at 225-2300C. 
Solubility:  
Soluble in cold water, forming a viscous colloidal solution,                                           
practically insoluble in chloroform, ethanol (95%) and ether, but soluble in mixtures 
of ethanol and dichloromethane. 
Stability and Storage:  
HPMC is a stable material although it is hygroscopic after drying. Solutions 
are stable between pH 3-11. Increasing temperature reduces the viscosity of solution. 
The gel point is 50-900C depending upon the grade of material. HPMC powder should 
be stored in a well-closed container, in a cool, dry place. 
Incompatabilites:  
It is incompatible with some oxidizing agents. Since it is                                           
non-ionic, hydrolxypropyl methylcellulose will not   complex with metallic salt and 
ionic organics to form insoluble precipitates. 
Applications:  
Widely used in oral and topical pharmaceutical formulations. In oral products, 
it is primarily used as a tablet binder, in film coating and as an extended release tablet 
matrix. Concentrations of between 2-5% w/w may be used as a binder in either wet or 
dry granulation processes. It is also used a suspending agent and thickening agent in 
topical formulations, particularly ophthalmic preparations. Used as adhesive in plastic 
bandages and as wetting agent for hard contact lenses. 
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4.4. SODIUM STARCH GLYCOLLATE: 23 
Nonproprietary Names 
BP         : Sodium starch glycolate. 
USPNF       : Sodium starch glycolate. 
Synonyms  : 
 Carboxy methyl starch, sodium salt, explo tab, primojel. 
Description: Sodium salt of carboxymethyl ether of starch. White to off-white, 
tasteless, odorless, relatively free flowing powder. Practically insoluble in organic 
solvents. Absorbs water rapidly, resulting in swelling which leads to rapid                                    
disintegration of tablets and granules. 
Molecular Formula  : C(CH2CO2Na)3 (CH2COO2Na) 
Functional Category  : Disintegrant, Suspending agent, Gelling agent 
Density (bulk)  : 0.85g/cm2. 
Density (tapped)  : 1.000g/cm2. 
Chemical Name  : Sodium carboxy methyl starch 
Empirical Formula  :  
The BP 1993 states that sodium starch glycolate is the  sodium salt of a poly-α-
glucopyranose in which some of the hydroxyl groups are in the form of the 
carboxymethyl ether. The USPNF XVII states that it is the sodium salt of a carboxy 
methyl ether of starch.  
Molecular Weight:  
The molecular weight is typically 500000 -1000000. Sodium starch glycolate 
may be characterized by the degree of substitution and cross linking.  
Applications:  
Dissolution aid for Tablets, capsules and pellets recommended concentration 
1.0 – 4.0%. May need to use up to 6.0% in wet granulation formulations, normally 
effective intra granularly.  However, may be more effective if added 50% intra 
granularly, and 50% extra-granularly (in the final dry mixture). 
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5. AIM AND PLAN OF WORK 
Carvedilol is Beta-adreno receptor antagonist which is used in treatment of 
hypertension and mainly in the treatment of congestive heart failure. 
 It is given as oral dosage form in the treatment of congestive heart failure and 
the management of hypertension. Its short biological half life 6 hrs and frequent 
administration (usually two times a day) make it a potential candidate for sustained 
release preparations. 
The bioavailability of Carvedilol is 25 %. 
Because of such pharmacokinetic characteristic the conventional dosage forms 
of the drug suffer the drawbacks of typical immediate release tablets. To overcome 
these drawbacks and also to overcome the side effects of the drug sustained release 
tablets can be prepared.  
 
5.1. THE SCOPE OF THE PRESENT WORK: 
• To provide a drug delivery system, which provides an initial burst release of 
the Carvedilol enough to take the plasma levels above the MEC and then 
provide a slow sustained release of the Carvedilol that maintains the plasma 
drug concentration above the MEC for an extended period of 12 hours.  
• To provide a drug delivery system for continuous release of drug at controlled 
rate to maintain the therapeutic blood plasma concentration for a required 
period of time.  
Finally to provide the drug delivery system which increases the patient 
compliance, effectiveness of therapy and reduces the chances of adverse effect and 
hypersensitivity of reaction by maintaining the plasma drug concentration at the same 
level with in therapeutic range for the required period of time.   
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5.2. PLAN OF WORK: 
The present work was carried out to design and evaluate sustained-release 
bilayer tablets of Carvedilol, an antihypertensive drug. The bilayered sustained release 
tablets were prepared by wet granulation method using Ethyl Cellulose, Eudragit 
RSPO, HPMC 4000, lactose, magnesium stearate, talc and sodium starch glycolate. 
Keeping in view the objectives described above the following plan of work was 
adopted: - 
• Preparation of standard calibration curve of Carvedilol. 
• Drug-excipients compatibility study by FTIR spectrophotometer. 
• Development of sustained release bilayer tablets using Ethyl cellulose, 
Eudragit RSPO, HPMC 4000 in three different concentrations by wet 
granulation method. 
• Evaluation of blend characteristics of prepared granules (Pre-compression 
parameters) 
1. Angle of repose. 
2. Determination of bulk density. 
3. Determination of tapped density. 
4. Compressibility index. 
5. Hausner’s Ratio. 
• To perform evaluation parameters like  (post-compression parameters)  
                              6.   Appearance.  
                              7.   Thickness. 
                              8.   Hardness. 
                              9.   Weight variation test. 
                             10.   Friability test. 
                             11.   Drug content uniformity. 
                             12.    In vitro dissolution studies. 
                             13.  Drug release kinetics data analysis. 
                             14.  Stability studies of the optimized formulation. 
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6. METHODOLOGY 
6.1. MATERIALS USED:  
Table No. 1. 
SR 
NO 
MATERIALS 
MANUFACTURERS/ 
SUPPLIERS 
1 Carvedilol Shasun Pharmaceuticals Ltd., 
Pondicherry. 
2 Ethyl Cellulose S.D. Fine Chem. Ltd., Mumbai 
3 Hydroxy Propyl Methyl Cellulose 4000 Ajantha Pharma, Mumbai 
4 Eudragit RSPO (Poly (ethylacrylate, 
methylmethacrylate) trimethyl ammonio 
ethyl methacrylate chloride. 1:2:0.1. 
Ajantha Pharma, Mumbai 
5 Sodium Starch Glycolate(SSG) Loba Chemi Pvt., Ltd., Mumbai 
6 Talc S.D. Fine Chem. Ltd., Mumbai 
7 Magnesium Stearate S.D. Fine Chem. Ltd., Mumbai. 
8 Starch Merck Specialities, Mumbai. 
9 Lactose S.D. Fine Chem. Ltd., Mumbai. 
10 Erythrosine Red A to Z Pharmaceuticals, Chennai 
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6.2. INSTRUMENTS USED   
Table No: 2 
SR. 
NO. 
INSTRUMENT MANUFACTURER/SUPPLIER 
1. Electronic Balance Sartorius, Germany. 
2. 
Rotary  tablet Compression Machine 
(10 stages) 
Rimek Mini Press I. 
3. Hardness Tester Monsanto. 
4. Friability Test Apparatus Roche friabilator. 
5. Vernier Calliper Inox- Somet,Japan. 
6. 
Dissolution Apparatus. 
 
Electro Lab. (USP XX III) 
(DTD – 06P). 
7 Double BeamUV Spectrophotometer Systronic Corporation, Mumbai. 
8 FTIR Spectrophotometer Perkin Elmer Spectrum, Japan. 
10 Digital pH Meter Eutech Instruments, Japan. 
11 Hot Air Oven Kemi, Mumbai. 
12 Melting Point Apparatus. Kemi, Mumbai. 
13 Bulk Density Apparatus. Kemi, Mumbai. 
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6.3. PREFORMULATION STUDIES24 
6.3.1. MELTING POINT:  
The melting point of Carvedilol was determined separately by using melting 
point apparatus.  
6.3.2. PREPARATION OF STANDARD CURVE: 
Preparation of standard curve of Carvedilol:  
The Carvedilol exhibits peak absorbance at 285 nm in dimethyl sulfoxide (DMSO) 
using Systronic double beam U.V. spectrophotometer. 
Procedure for standard curve: 
 Weigh accurately 100mg of Carvedilol and dissolve it in 10 ml of DMSO, then 
make up the volume upto 100ml with DMSO (primary stock solution). From the 
primary stock solution take 10ml of solution and make up to 100ml with DMSO, this 
is the secondary stock solution. Several dilutions were made from this secondary stock 
solution, to obtain a concentration range of 1-5 µg/ml. The absorbance was measured 
at 285 nm using DMSO as blank and plotted to get the calibration curve. 
6.3.3. Fourier Transform Infrared Spectrophotometer (FTIR):25 
This is another parameter involved in the preformulation studies. This study 
involves finding out the compatibility of the drug with that of the polymer used. The 
study of drug with the excipients was determined by I.R. Spectroscopy (FTIR) using 
Perkin Elmer spectrum RX1 FT-IR spectrometer model. The pellets were prepared at 
high compaction pressure by using KBr and the ratio of sample to KBr is 1:100. The 
pellets thus prepared were examined and the spectra of drug and other ingredients in 
the formulations were compared with that of the original spectra.  
The FTIR of pure Carvedilol was taken and is shown in FTIR spectrum. Also 
the FTIR of Carvedilol with the polymers like Eudragit RSPO, Ethyl Cellulose and 
HPMC 4000 was taken individually. Also the FTIR of Carvedilol with Sodium Starch 
Glycolate was taken individually. 
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6.4. FORMULATION OF SUSTAINED RELEASE BILAYER MATRIX 
TABLETS OF CARVEDILOL26 
Calculation of Loading and Maintenance dose: 
The formulation involves the calculation of loading dose (Di), desired release 
rate(Ks), maintenance dose (Dm) and total dose required for Carvedilol bilayered  SR 
matrix tablets as follows: 
Oral dose     : 25mg 
Dosing Interval (τ)    : 12 hrs 
Elimination Half-life (t1/2)   : 6 hrs 
Time of peak plasma concentration (tp) : 1.5 hrs 
Elimination rate constant (Ke)  : 0.693/ t1/2 
  = 0.693/6  
= 0.1155 
Initial dose (Di): Css.Vd/F 
But, Css  = F.Xo/Ke.Vd.τ 
Thus, Di  = F.Xo/Ke.Vd.τ * Vd/F 
= Xo/ Ke.τ 
= 25/0.1155*12 
= 18.03 
Desired rate of drug release (Ks): Di*Ke 
= 18.03*0.1155 
=2.0824 mg/hr 
Maintenance dose (Dm): Ks* τ 
= 2.0824*12 
= 24.988 mg (25mg) 
 
Corrected Initial dose (Di*): Di – (Ks*tp) 
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= 18.03 – (2.0824*1.5) 
= 14.90 mg (15mg) 
Total dose (Dt): Dm+Di* 
 = 24.988+14.90 
= 39.888 mg (40 mg) 
6.4.1. PREPARATION OF SUSTAINED RELEASE BILAYER MATRIX    
TABLETS OF CARVEDILOL:13,27,28 
 The bilayer tablets of Carvedilol were prepared by the wet granulation method. 
The drug and polymers for both fast release and sustaining layer were passed through 
sieve number 44 before their use in the formulation. 
Preparation of Immediate Releasing (Loading Dose) Layer: 
 Wet granulation method was followed to formulate the immediate release 
granules containing Carvedilol. Fast releasing granules was prepared by mixing 
Carvedilol with Sodium Starch Glycolate as disintegrating agent and starch paste as 
binder (which was previously mixed with Erythrosine Red as a colouring agent). The 
cohesive mass was passed through sieve number 22, and then it was dried at 60°C for 
half an hour in an oven. The granules were mixed with excipients like talc and 
magnesium stearate. 
Preparation of sustained release layer. 
 The same wet granulation method was followed to formulate the sustained 
release granules containing Carvedilol. The drug was mixed with different polymers 
namely Eudragit RSPO, Ethyl Cellulose and HPMC 4000. Three different ratios of 
drug with polymer was selected (1:1, 1:2, 1:3) for each of the polymer, and totally 
nine formulations was formulated and named as from F1 – F3, F4–F6, F7–F9 
containing HPMC 4000, Ethyl Cellulose, Eudragit RSPO respectively. Lactose was 
mixed with each drug polymer ratio. Starch paste (10%w/v) was added as binder. 
Excipients like talc and magnesium stearate was added to each of the formulations.  
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Compression of bilayer tablet 
 Required quantity of granules containing Carvedilol for the sustained release 
layer was first compressed lightly using a rotary tablet punching machine equipped 
with 11/32 round punch.  Over this compressed layer, the required quantity of 
granules containing Carvedilol as fast release layer was placed and was compressed to 
obtain bilayer matrix tablets of Carvedilol. 
Parameters fixed for tablet: 
1. Tablet weight : 300 mg ± 20mg 
2. Thickness : 2.4 ± 0.5 mm 
3. Hardness : 4.2 ± 0.5 kg/cm2 
4. Friability : Not more than 1%. 
                    Formulas of bilayered matrix tablets of carvedilol: 
Formula of immediate releasing layer. 
Table No. 3 
INGREDIENTS QUANTITY FOR A SINGLE TABLET(mg) 
Carvedilol 15 
Sodium Starch Glycolate 5 
Starch Paste (10%) 10 
Lactose 65 
Magnesium Stearate 2 
Talc Powder 3 
Erythrosine Red q.s 
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FORMULA OF SUSTAINED LAYER: 
Table No. 4 
Form 
Code 
Carvedilol HPMC 
4000 
Ethyl 
Cellulose 
Eudragit 
RSPO 
Lactose Starch 
Paste 
Talc Magnesium 
Strearate 
F1 25 12.5 - - 157.5 q.s. 3 2 
F2 25 25 - - 145 q.s. 3 2 
F3 25 37.5 - - 132.5 q.s. 3 2 
F4 25 - 12.5 - 157.5 q.s. 3 2 
F5 25 - 25 - 145 q.s. 3 2 
F6 25 - 37.5  132.5 q.s. 3 2 
F7 25 - - 12.5 157.5 q.s. 3 2 
F8 25 - - 25 145 q.s. 3 2 
F9 25 - - 37.5 132.5 q.s. 3 2 
All weights are taken in mg 
 
 
 
 
 
 
 
 
 
 
 
Development and Evaluation of Sustained Release Bilayer Tablets of Carvedilol  
 
Dept. of Pharmaceutics, The Erode College of Pharmacy and Research Institute. Page 49 
 
6.5.  EVALUATION OF BLEND CHARACTERISTICS OF CARVEDILOL 
GRANULES: 29,30 
1. Angle of repose: 
The flow property of the granules was determined by measuring the Angle of 
Repose. It is the maximum angle that can be obtained between the freestanding 
surface of a powder heap and the horizontal plane. Values of θ are rarely less than 20o, 
and values of up to 40o indicate reasonable flow potential. Above 50o, however, the 
powder flows only with difficulty if at all. 
  θ = Tan-1 (h/r) 
Where, 
h = Height the pile. 
r = Radius of the pile. 
θ = Angle of repose. 
A funnel was fixed in a holder; the tip of the funnel was placed at a height of 6 
cms from the surface. A graph sheet was placed below the funnel. 5 gms of the sample 
was taken and was passed slowly through the funnel. The height of the powder heap 
formed was measured. The circumference of the heap formed was drawn with a pencil 
on the graph paper. The radius was determined and the angle of response was 
determined using the given formula. The same procedure was repeated 3 times for 
each sample. 
2. Determination of bulk density and tapped density: 
20 g of the powder (W) from each formula was introduced individually into a 
100ml of measuring cylinder. After that the initial volume was noted, the cylinder was 
kept in bulk density apparatus for tapping. The tapping was continued for 100 times 
and the change in volume was noted. 
The bulk density, and tapped density were calculated using the following 
formulas: -  
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                      Bulk density = W / V0 
                 Tapped density = W / Vf 
Where, 
W = Weight of the powder. 
V0 = Initial volume. 
Vf = Final volume. 
The results were presented in the table no:10 
3. Compressibility index (Carr’s index): 
 Compressibility index is an important measure which can be obtained from 
bulk and tapped densities. Theoretically, the less compressible a material the more 
flowable it is. 
 This shows that a material having value of less than 18 % is defined as the free 
flowing material. 
CI   = 100 (V0  - Vf) /  V0 
Where, 
           CI   = Compressibility index. 
4. Hausner’s Ratio: 
 This indicates the flow properties of the powder and is measured by the ratio 
of tapped density to the bulk density. 
 Hauser’s Ratio = (W / Vf  ) / (W / V0) 
Where, 
 W / Vf = Tapped density.  
 W / V0 = Bulk density.  
Thus, 
Hauser’s Ratio = Tapped density/Bulk density. 
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6.5.1.  EVALUATION OF BILAYERED TABLETS OF CARVEDILOL: 12, 13,28 
 The following evaluations tests were performed for the prepared tablets of 
bilayered tablets containg Carvedilol:  
Thickness, Hardness, Friability and Weight variation test. 
Content uniformity test. 
In-Vitro drug release study. 
1. Tablet Thickness: 
 The thickness of the tablet was measured with Vernier Calliper. Five tablets 
were selected from each formulations and the test was performed.  
      2.   Hardness Test: 
 Hardness test was carried out by using “Monsanto” hardness tester. Five 
tablets were randomly selected from each of the formulations and the test was carried 
out.  
      3.   Friability Test: 
  “Roche” friabilator is used to determine the friability of the tablets. For 
determining the friability of the tablets 10 tablets were taken and weighed. After 
weighing the tablets were placed in the Roche friabilator and was allowed for the 
combined effects of abrasion and shock by utilizing a plastic chamber which was then 
allowed to revolve at 25 rpm for 4 minutes, this drops the tablets from a height of six 
inches with each revolution. After undergoing this procedure the tablets were dedusted 
and reweighed.  
Friability can be determined by  
 
Where, 
 Wo = weight of tablets before friability test. 
 Wt = weight of tablets after friability test. 
 
F = 100 (1-Wt/Wo) 
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4. Weight Variation Test: 
 Twenty tablets were selected at random and the average weight was 
determined. Not more than two of the individual tablet’s weights should deviate from 
the average weight by more than the percentage deviation shown in table and none 
should deviates by more than twice the percentage.  
 
WEIGHT VARIATION TOLERANCES FOR UNCOATED TABLETS. 
Table No. 5 
S. No. Average weight of Tablets (mg) 
Maximum percentage difference 
allowed 
1. 130 or Less 10 
2. 130 to 324 7.5 
3. More than 324 5.0 
% Maximum positive deviation = (WH –A/ A) x 100 
% Minimum negative deviation = (A-WL/ A) x 100 
Where,   
WH  =  Highest weight in mg. 
WL  =  Lowest weight in mg. 
            A  =  Average weight of tablet in mg. 
5. Drug content uniformity: 27,31,32   
Ten tablets were finely powdered and an amount equivalent to 50 mg of 
Carvedilol was weighed accurately and transferred to a 100 ml volumetric flask, then 
70 ml of ethanol was added. The flask was shaken for 10 min. Finally, the volume was 
made up to the mark with ethanol. The mixture was then filtered and 1 ml of the 
filtrate was diluted with ethanol to obtain a solution containing about 10 – 50 µg/ml of 
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Carvedilol and analyzed at 285 nm using a double beam UV/Visible 
spectrophotometer and ethanol as blank. 
6. In vitro dissolution studies 
 In vitro dissolution test for the tablet of each formulation was carried out using 
USP dissolution type II apparatus using paddle, fixing the tablet to the paddle at 50 
rpm. The dissolution was carried out using 900 ml of Acid buffer (pH 1.2) for the first 
2 hrs which was then followed by Phosphate buffer (pH 6.8) for the remaining hours. 
The temperature was maintained at 37 ± 0.2 °C. 5ml of the sample was withdrawn at 
different time intervals, i.e. 5, 15, 30, 60, 120, 180, 240, 300, 360, 480, 600 and 720 
min, and the same quantity was replaced with freshly prepared acid buffer and 
phosphate buffer respectively. The withdrawn sample was filtered through Whatmann 
filter paper. Samples were suitably diluted and release of the drug was determined 
using UV/Visible spectrophotometer under the wavelength of 285nm. 
Details of dissolution test: 
Dissolution test apparatus  :  USP  
Speed     :  50 rpm 
Stirrer     :  Paddle type 
Volume of medium   :  900 ml 
Aliquot taken at each time interval :  5 ml 
            Medium used                            :  Acid buffer (pH 1.2),        
                                                                        :  Phospahte buffer (pH 6.8). 
Temperature    :  37 ± 0.5 0C 
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In vitro dissolution studies for marketed tablet: 
In order to compare the drug release rate of the bilayer tablet with the 
marketed tablet the dissolution study of the marketed tablet was carried out in the 
same condition as mentioned above but only in phosphate buffer (pH 6.8).  
 
6.5.2. KINETIC ANALYSIS OF IN-VITRO RELEASE RATES OF BILAYER 
TABLETS OFCARVEDILOL: 33 
The results of in vitro release profile obtained for all the formulations were 
plotted in modes of data treatment as follows: -  
1. Zero - order kinetic model: This follows, Cumulative % drug released Vs time. 
2. First – order kinetic model: This follows, Log cumulative percent drug 
remaining Vs time. 
3.  Higuchi’s model: This follows, Cumulative percent drug released Vs square 
root of time. 
4. Korsmeyer equation / Peppa’s model: This follows, Log cumulative percent 
drug released Vs log time. 
1. Zero order kinetics:  
Zero order release would be predicted by the following equation: - 
 At = A0 – K0t 
Where,  
 
At  = Drug release at time ‘t’. 
 A0 = Initial drug concentration. 
  K0 = Zero - order rate constant (hr-1). 
When the data is plotted as cumulative percent drug release Vs time, if the plot 
is linear then the data obeys Zero – order kinetics and its slope is equal to Zero order 
release constant K0. 
2. First Order Kinetics: 
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First – order release would be predicted by the following equation: - 
Log C = log C0 – Kt / 2.303 
Where,  
C   = Amount of drug remained at time‘t’. 
C0  = Initial amount of drug. 
K   = First – order rate constant (hr-1). 
When the data plotted as log percent drug remaining Vs time, yields a straight 
line, this indicates that the release follows first order kinetics. The constant ‘K1’ can 
be obtained by multiplying 2.303 with the slope value. 
3. Higuchi’s model: 
Drug release from the matrix devices by diffusion has been described by 
following Higuchi’s classical diffusion equation: - 
Q = [Dε / τ (2 A - εCs) Cst] ½ 
Where, 
Q = Amount of drug released at time‘t’. 
D = Diffusion coefficient of the drug in the matrix. 
A = Total amount of drug in unit volume of matrix. 
Cs = the solubility of the drug in the matrix. 
ε = Porosity of the matrix. 
τ = Tortuosity. 
t = Time (hrs) at which ‘q’ amount of drug is released. 
 Above equation may be simplified if one assumes that ‘D’, ‘Cs’ and ‘A’ are 
constant. Then equation becomes: -            
Q = Kt1/2 
When the data is plotted according to equation i.e. cumulative drug release Vs 
square root of time yields a straight line, this indicates that the drug was released by 
diffusion mechanism. The slope is equal to ‘K’ (Higuchi’s 1963). 
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4. Korsmeyer equation / Peppa’s model:  
 To study the mechanism of drug release from the sustained-release matrix 
tablets of Diltiazem Hydrochloride, the release data was fitted to a well-known 
exponential equation (Korsmeyer equation/ peppa’s law equation), which is often used 
to describe the drug release behaviour from polymeric systems. 
Mt / Mα = Ktn 
Where, 
Mt / Mα = The fraction of drug released at time‘t’. 
K = Constant incorporating the structural and geometrical characteristics of the 
drug / polymer system. 
n = Diffusion exponent related to the mechanism of the release. 
 Above equation can be simplified by applying log on both sides, 
And we get: -  
   Log Mt / Mα = Log K + n Log t 
MECHANISM OF DRUG RELEASE AS PER KORSMEYER EQUATION / 
PEPPA’S MODEL.  
Table No. 6 
S. No. n Value Drug release 
1.  < 0.45 Fickian release 
2.  0.45 <1.0 Non – Fickian release 
3.  > 1.0 Class II transport 
When the data is plotted as log of % cumulative drug released Vs log time, it 
yields a straight line with a slope equal to ‘n’. For Fickian release ‘n’ = 0.45 while for 
anomalous (non - Fickian) transport ‘n’ ranges between 0.45 and 1.0.  
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6.6. STABILITY STUDIES OF THE OPTIMIZED FORMULATION 
Stability of a pharmaceutical preparation can be defined as “the capability of a 
particular formulation in a specific container/closure system to remain within its 
physical, chemical, microbiological, therapeutic and toxicological specifications 
throughout its shelf life.” 
Hence the purpose of stability testing is to provide evidence on how the quality 
of a drug substance or drug product varies with time under influence of a variety of 
environmental factors such as temperature, humidity and light, and enables 
recommended storage conditions, re-test periods and shelf-lives to be established. 
ICH specifies the length of study and storage conditions: 
Long term testing: 250C ± 20C /60% RH ± 5% RH for 12 months. 
Accelerated testing: 400C ± 20C /75% RH ± 5% RH for 6 months. 
Procedure: 
 In the present study, stability studies were carried out at 400C ± 20C for a time 
period of 90 days for selected optimized formulations. 
 For stability study, the tablets were placed in an ambered coloured vials and 
sealed with aluminum foil. These sample containers were placed in desiccator. 
Evaluation of samples: 
 The samples were analyzed for the following parameter, 
Physical evaluation: 
Appearance: The samples were checked for any change in colour at every week. 
Hardness: The samples were tested for hardness at every week. 
Chemical evaluation: 
Drug content: The samples were checked for drug content. 
Drug release: The samples were subjected to drug release studies. 
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7. RESULTS 
7.1. PREFORMULATION STUDIES 
7.1.1.  Melting point: 
 The melting point of Carvedilol was found to be 114.2oC, which is within the 
reported value (114 to 115oC).  
  The melting point of both the drugs complies with their individual 
standards thus indicating the purity of the drug sample. 
 
 
 
Photo 1. Shows the external appearance of the bilayer tablets of formulation F3 
containing HPMC 4000.
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7.1.2. Preparation of calibration curve of Carvedilol:    
STANDARD CURVE OF CARVEDILOL IN ACID BUFFER (pH 1.2) 
Table No: 7 
Concentration 
(µg/ml) 
Absorbance 
( nm) 
1 0.091 
2 0.183 
3 0.271 
4 0.360 
5 0.452 
 
STANDARD CURVE OF CARVEDILOL IN ACID BUFFER (pH 1.2) 
Graph No: 1 
 
Slope                      = 0.090 
  Correlation coefficient     = 1.000 
STANDARD CURVE OF CARVEDILOL IN PHOSPHATE BUFFER (pH 6.8) 
y = 0.090x + 0.000
R² = 1
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Standard curve of carvedilol with acid buffer (pH 1.2) 
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Table No: 8 
Concentration 
(µg/ml) 
Absorbance 
( nm) 
1 0.121 
2 0.232 
3 0.350 
4 0.461 
5 0.582 
 
Standard curve of carvedilol in phosphate buffer (ph6.8) 
Graph No: 2 
 
Slope                      = 0.1150 
  Correlation coefficient     = 0.999 
 
 
 
y = 0.115x + 0.001
R² = 0.999
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 1 2 3 4 5 6
A
bs
o
rb
a
n
ce
Conc (µg/ml)
Standard curve of carvedilol with phosphate buffer (pH 6.8)
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FTIR SPECTRA OF CARVEDILOL 
Spectra no 7.1 
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FTIR SPECTRA OF HPMC 4000 
Spectra no 7.2 
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FTIR SPECTRA OF ETHYL CELLULOSE 
Spectra no 7.3 
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FTIR SPECTRA OF EUDRAGIT RSPO 
Spectra no 7.4 
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FTIR SPECTRA OF SODIUM STARCH GLYCOLATE 
Spectra no 7.5 
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FTIR SPECTRA OF CARVEDILOL + HPMC 4000 
Spectra no 7.6 
 
Development and Evaluation of Sustained Release Bilayer Tablets of Carvedilol  
 
Dept. of Pharmaceutics, The Erode College of Pharmacy and Research Institute. Page 67 
 
FTIR SPECTRA OF CARVEDILOL + ETHYL CELLULOSE 
Spectra no 7.7 
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FTIR SPECTRA OF CARVEDILOL + EUDRAGIT RSPO 
Spectra no 7.8 
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FTIR SPECTRA OF CARVEDILOL + SODIUM STARCH GLYCOLATE 
Spectra no 7.9 
 
 
Development and Evaluation of Sustained Release Bilayer Tablets of Carvedilol  
 
Dept. of Pharmaceutics, The Erode College of Pharmacy and Research Institute. Page 70 
 
ASSESMENT OF THE FUNCTIONAL GROUPS OF CARVEDILOL 
OBTAINED IN FTIR SPECTRA OF COMPATIBILITY STUDIES. 
 Table 9 
S. NO FUNCTIONAL GROUP STANDARD 
IR RANGE 
cm -1 
ASSESMENT  PEAKS 
OF PURE DRUG cm -1 
1 Secondary amine  (N-H 
stretching) 
3500-3300 3344.68 
2 Secondary alcohol  1350-1260 1305.85 
3 Aromatic  3050-3000 3058.24 
4 C-H 2960-2850 2923.22 
5 Aromatic hydrocarbons 1600 1606.76 
6 Disubstituted (ortho) 770-735 752.26 
7 -OCH3 stretching  Below 3000 2923.22 
8 C=C stretching in aromatic 
nuclei 
1700-1400 1449.55, 1504.53, 
1589.40, 
1606.76,1629.90 
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 GRANULAR PROPERTIES OF FORMULATIONS 
Table 10  
Formulation 
Code 
Angle 
of 
Repose 
Bulk 
Density 
(gm/cm2) 
Tapped 
Density 
(gm/cm2) 
Compressibility 
Index (%) 
Hauser’s 
Ratio 
F1 23014” 0.740 0.869 14.814 1.174 
F2 25042” 0.714 0.800 10.714 1.120 
F3 24033” 0.689 0.769 10.344 1.116 
F4 25045” 0.769 0.869 11.538 1.130 
F5 26038” 0.714 0.833 14.285 1.166 
F6 24034” 0.689 0.800 13.793 1.161 
F7 23044” 0.769 0.869 11.538 1.130 
F8 26036” 0.740 0.833 11.111 1.125 
F9 24044” 0.714 0.833 14.285 1.166 
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TABLETING PROPERTIES OF BILAYER TABLETS CONTAINING 
CAEVEDILOL 
Table 11 
Form 
Code 
Evaluation Parameters 
Thickness 
±S.D. 
(mm) 
Hardness 
±S.D. 
(Kg/cm2) 
Friability 
±S.D. (%) 
Average 
Weight 
variation 
Disintegration 
(secs) 
Drug 
Content 
(%) 
F1 2.43±0.05 4.3±0.15 0.197±0.01
0 
300±2.08 33±2.64 91.66±1.
52 
F2 2.36±0.05 4.2±0.11 0.264±0.00
2 
299±2.64 36±1.15 93.66±0.
57 
F3 2.40±0.10 4.2±0.05 0.652±0.00
6 
301±3.00 37±1.15 97.33±1.
15 
F4 2.46±0.05 4.4±0.05 0.663±0.00
5 
300±0.57 34±0.57 92.66±0.
57 
F5 2.46±0.05 4.3±0.05 0.265±0.00
1 
298±3.46 37±1.00 95.00±1.
00 
F6 2.43±0.05 4.3±0.10 0.262±0.00
2 
298±1.15 36±1.00 94.00±1.
00 
F7 2.33±0.05 4.3±0.10 0.317±0.02
3 
301±0.57 37±0.57 93.66±1.
52 
F8 2.46±0.05 4.3±0.15 0.532±0.00
2 
302±0.46 36±1.00 94.33±0.
57 
F9 2.43±0.05 4.4±0.10 0.525±0.00
5 
298±2.00 36±0.57 96.33±0.
57 
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DRUG RELEASE PROFILE FOR F1 FORMULATION CONTAINING HPMC 
4000 
Table 12  
S. No Formulation Type Time (Mins) Cumulative % 
Drug Release 
% Drug 
Release 
1  
Immediate Release 
5 1.19 11.90 
2 15 5.21 20.10 
3 30 8.85 34.20 
4 60 12.06 13.20 
5 120 16.78 62.30 
6  
 
Sustained Release 
180 1.54 6.19 
7 240 6.21 9.32 
8 300 8.60 12.55 
9 420 15.11 23.94 
10 540 21.59 31.21 
11 660 28.07 40.53 
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DRUG RELEASE PROFILE FOR F2 FORMULATION CONTAINING HPMC 
4000 
Table 13  
S. No Formulation Type Time (Mins) Cumulative % 
Drug Release 
% Drug 
Release 
1  
Immediate Release 
5 1.02 10.2 
2 15 6.86 29.2 
3 30 12.2 46.4 
4 60 17.28 63.2 
5 120 23.44 85.6 
6  
 
Sustained Release 
180 0.79 3.19 
7 240 4.02 6.44 
8 300 9.62 16.02 
9 420 18.97 29.92 
10 540 31.93 48.89 
11 660 50.66 76.88 
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 DRUG RELEASE PROFILE FOR F3 FORMULATION CONTAINING HPMC 
4000 
Table 14  
S. No Formulation Type Time (Mins) Cumulative % 
Drug Release 
% Drug 
Release 
1  
Immediate Release 
5 1.08 10.8 
2 15 5.12 20.2 
3 30 9.98 39.8 
4 60 16.02 60.2 
5 120 24.00 89.90 
6  
 
Sustained Release 
180 1.03 4.13 
7 240 5.50 8.95 
8 300 11.98 19.50 
9 420 24.12 38.50 
10 540 40.71 62.17 
11 660 62.01 92.94 
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DRUG RELEASE PROFILE FOR F4 FORMULATION CONTAINING 
ETHYL CELLULOSE  
Table 15  
S. No Formulation Type Time (Mins) Cumulative % 
Drug Release 
% Drug 
Release 
1  
Immediate Release 
5 1.12 11.20 
2 15 5.10 19.90 
3 30 9.35 36.80 
4 60 16.14 62.30 
5 120 23.29 85.30 
6  
 
Sustained Release 
180 1.54 6.19 
7 240 7.68 12.27 
8 300 11.53 16.93 
9 420 18.16 27.86 
10 540 31.50 49.08 
11 660 43.35 62.17 
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DRUG RELEASE PROFILE FOR F5 FORMULATION CONTAINING 
ETHYL CELLULOSE  
Table 16 
S. No Formulation Type Time (Mins) Cumulative % 
Drug Release 
% Drug 
Release 
1  
Immediate Release 
5 1.08 10.80 
2 15 6.96 29.40 
3 30 12.26 46.60 
4 60 17.34 63.40 
5 120 23.70 86.80 
6  
 
Sustained Release 
180 0.82 3.31 
7 240 4.11 6.57 
8 300 9.87 16.46 
9 420 19.14 30.05 
10 540 32.02 49.02 
11 660 50.76 77.00 
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DRUG RELEASE PROFILE FOR F6 FORMULATION CONTAINING 
ETHYL CELLULOSE  
Table 17  
S. No Formulation Type Time (Mins) Cumulative % 
Drug Release 
% Drug 
Release 
1  
Immediate Release 
5 1.00 10.00 
2 15 4.80 19.00 
3 30 9.70 39.00 
4 60 15.74 59.20 
5 120 23.16 86.20 
6  
 
Sustained Release 
180 0.95 3.81 
7 240 5.27 8.64 
8 300 11.44 18.56 
9 420 22.95 36.62 
10 540 38.88 59.44 
11 660 58.54 87.37 
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DRUG RELEASE PROFILE FOR F7 FORMULATION CONTAINING 
EUDRAGIT RSPO  
Table 18  
S. No Formulation Type Time (Mins) Cumulative % 
Drug Release 
% Drug 
Release 
1  
Immediate Release 
5 1.13 11.30 
2 15 5.15 20.10 
3 30 9.39 36.90 
4 60 16.21 62.60 
5 120 23.38 85.60 
6  
 
Sustained Release 
180 1.55 6.22 
7 240 7.78 12.45 
8 300 11.66 17.09 
9 420 18.51 28.48 
10 540 31.72 49.21 
11 660 43.46 62.32 
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DRUG RELEASE PROFILE FOR F8 FORMULATION CONTAINING 
EUDRAGIT RSPO  
Table 19 
S. No Formulation Type Time (Mins) Cumulative % 
Drug Release 
% Drug 
Release 
1  
Immediate Release 
5 1.07 10.70 
2 15 6.93 29.30 
3 30 12.21 46.40 
4 60 17.28 63.20 
5 120 23.60 86.40 
6  
 
Sustained Release 
180 0.83 3.34 
7 240 4.43 7.20 
8 300 10.06 16.52 
9 420 19.48 30.70 
10 540 32.22 49.08 
11 660 50.14 75.75 
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DRUG RELEASE PROFILE FOR F9 FORMULATION CONTAINING 
EUDRAGIT RSPO  
Table 20  
S. No Formulation Type Time (Mins) Cumulative % 
Drug Release 
% Drug 
Release 
1  
Immediate Release 
5 1.04 10.40 
2 15 5.44 22.00 
3 30 10.40 41.00 
4 60 16.12 60.10 
5 120 23.49 87.40 
6  
 
Sustained Release 
180 0.96 3.85 
7 240 5.31 8.70 
8 300 11.50 18.65 
9 420 23.46 37.59 
10 540 39.49 60.19 
11 660 60.20 90.31 
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DRUG RELEASE PROFILE FOR MARKETED TABLET 
Table 21  
S. No Formulation Type Time (Mins) Cumulative % 
Drug Release 
% Drug 
Release 
1  
 
Conventional 
30 1.95 7.82 
2 60 7.46 11.01 
3 180 16.27 27.04 
4 300 29.45 45.39 
5 420 45.46 68.24 
6 720 65.03 95.94 
 
 
 
 
 
Graph 3: Shows zero order kinetics of F1, F4, F7 
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Graph 4: Shows zero order kinetics of F2, F5, F8 
 
 
 
 
Graph 5: Shows zero order kinetics of F3, F6, F9 
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Graph 6: Shows first order kinetics of F1, F4, F7 
 
 
 
Graph 7: Shows first order kinetics of F2, F5, F8 
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Graph 8: Shows first order kinetics of F3, F6, F9 
 
 
Graph 9: Shows  higuchi model for F1, F4, F7 
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Graph 10: Shows  higuchi model for F2, F5, F8 
 
 
Graph 11: Shows  higuchi model for F3, F6, F9 
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Graph 12: Shows  peppa’s model for F1, F4, F7 
 
 
 
Graph 13: Shows  peppa’s model for F2, F5, F8 
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Graph 14: Shows  peppa’s model for F3, F6, F9 
 
Curve fitting data of release rate profile of formulation F1 to F5  
Table 22 
METHOD FORMULATION CODE 
F1 F2 F3 F4 F5 
Zero order R2 0.997 0.976 0.983 0.987 0.977 
First order R2 0.954 0.927 0.936 0.950 0.925 
Higuchi R2 0.744 0.623 0.633 0.691 0.625 
Peppa’s R2 0.922 0.973 0.943 0.919 0.969 
n 0.421 0.595 0.6388 4.794 0.599 
 
Curve fitting data of release rate profile of formulation F6 to F9  
Table 23 
METHOD FORMULATION CODE 
F6 F7 F8 F9 
Zero order R2 0.984 0.988 0.981 0.981 
First order R2 0.923 0.948 0.923 0.924 
Higuchi R2 0.635 0.694 0.633 0.633 
Peppa’s R2 0.947 0.917 0.963 0.947 
n 0.603 0.478 0.592 0.635 
 
7.1.3. AFTER STABILITY STUDIES: 
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   The Formulation F3 containing HPMC 4000 was selected for Stability studies 
for the period of three months. The following results were obtained: 
 
TABLETING PROPERTIES OF BILAYER TABLETS OF F3 CONTAINING 
HPMC 4000 AFTER STABILITY STUDY 
Table 24 
S. No Parameters Formulation (F3 HPMC 4000) 
1 Weight Variation 299±2.64 
2 Hardness ± SD (kg/cm3) 4.2±0.05 
3 Friability ± SD (%) 0.652±0.006 
4 Thickness ± SD (mm) 2.40±0.10 
5 Disintegration Time (sec) 36±1.15 
6 Drug Content 96.25±1.15 
7 % Drug Release 91.96 
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8. DISCUSSION 
8.1 Determination of Melting point of Carvedilol. 
 Melting point of both the drugs was found to be within the reported limit. It 
complies with standards thus indicating the purity of the drug sample. 
8.2 Preparation of standard curve of Carvedilol : 
 From the standard curve of Carvedilol it was observed that the drug obeys 
beer’s law in concentration range of 1-5 µg/ml in acid buffer (pH 1.2) and phosphate 
buffer (pH6.8). 
8.3 Determination of IR spectrum of Carvedilol: 
 The FTIR spectral analysis showed that there was no appearance or 
disappearance of any characteristic peaks of pure drug of Carvedilol in the physical 
mixture of drug and polymer, which confirms the absence of chemical interaction 
between drug and polymers.  
8.4 Formulation: 
 Nine formulations of sustained release bilayer tablets were prepared using  
polymers such as Eudragit RSPO, Ethyl cellulose, and HPMC 4000 in different 
concentrations and proportions by wet granulation technique in sustaining layer and 
sodium starch glycolate is used as super disintegrent in immediate release layer. All 
the formulations were prepared by keeping constant tablet weight (300 mg ± 20mg) 
and hardness (4.2 ± 0.5 kg/cm2). 
8.5 Evaluation parameters: 
Physicochemical evaluation : 
The granules were prepared by wet granulation method and preformulation 
studies were carried out. The granules of all the batches exhibited good flow 
characteristics evident from the results of their physicochemical evaluations. The 
angle of repose value ranged from 23014” to 26038”. The results were found to be 
below 280 and hence the blend showed to have good flow ability. Bulk and tapped 
densities are used for the measurement of Compressibility index. The BD ranged from 
0.689 to 0.769 
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while TD ranged from 0.769 to   0.869. The compressibility index (%) was   
calculated form the BD and it ranged from 10.344 to 14.814. The blend was found to 
have free flowing property as the result were found to be below 20%. The Hauser’s 
ratio ranged from1.116 to 1.174. The result indicates the free flowing properties of the 
granules as the value was below 1.2.  
The prepared tablets were subjected to evaluation tests such as hardness, 
thickness, % weight variation, friability and drug content. All the nine formulations 
had shown results for these characteristics within the acceptable ranges.  
In vitro drug release profile: 
  From the results of in vitro release study, it was observed that the 
release of Carvedilol from the prepared formulations was analyzed by plotting the 
cumulative percent drug released vs. time. Simple visual observation of the plot shows 
an initial burst effect. From all the formulations, over of the drug was released within 
120 minutes of the dissolution study. This initial high amount of drug release can be 
attributed the immediate release layer of the formulation. Further release of drug was 
studied for 12 hrs. Eudragit RSPO, Ethyl cellulose and HPMC 4000 has been used as 
release retardant polymer in controlled release dosage forms. Ethyl Cellulose reduces 
the drug release due to a reduction in the penetration of the solvent molecules into the 
system because of the hydrophobic nature of ethyl cellulose present on the surface of 
the tablet, i.e. the rate of release is controlled by the permeability of matrix structure.  
Graph shows that formulation F1, F4, F7 containing HPMC 4000, Ethyl Cellulose, 
Eudragit RSPO could not sustain release beyond 40.53%, 62.17%, and 62.32% 
respectively over the period of 12 hrs. However, the formulation F3, F6, F9 containing 
HPMC 4000, ethyl cellulose and Eudragit RSPO which showed a release rate of 
92.94%, 87.37% and 90.31% respectively. And hence F3 containing HPMC 4000 
which showed a release rate of 92.94% was selected as optimized formulations, 
because they could sustain the release rate of drug for 12 hrs. As the formulation 
containing Eudragit RSPO swells more in aqueous medium and the release rate of F6 
containing ethyl cellulose is less when compared to F3 HPMC 4000. Hence the 
formulation F3 containing HPMC 4000 is considered the optimized formulation. 
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The optimized formulation of F3 was compared with the marketed tablet of 
Carvedilol with respect to the in-vitro dissolution studies for its sustained action. The 
release rate of F3 was found to be nearly equal to the release rate of the marketed 
tablet. 
Curve fitting data analysis: 
The curve fitting results of the release rate profile of the designed formulations 
gave an idea on the mechanism of drug release. Data of in vitro release was fitted to 
various models like Korsmeyers-peppas, Zero order, First order, and Higuchi matrix.  
From the values for diffusion coefficient (n), it was found that all the formulations 
follows Fickian’s release mechanism, except formulation HPMC 4000 which follows 
non-fickian’s release mechanism.  
RANGE FOR VALUE OF KORSMEYERS-PEPPAS MODEL FOR 
FORMULATIONS 
Table 25 
Krosmeyers-peppas Range 
R2 0.8206 – 0.8529  
Y 0.2322 – 0.2693  
n 0.22-0.25 
 
8.6.STABILITY STUDIES:  
 The results of stability study, which was carried for 90 days, showed that there 
was no significant change in colour; drug content, hardness, friability, disintegration 
time and in vitro drug. But just showed a slight decrease in the parameters which falls 
in the acceptable range. 
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9. SUMMARY AND CONCLUSION 
9.1.SUMMARY: 
 Carvedilol is a non selective β-blocker antagonist, which is used in treatment 
of CHF and hypertension. Carvedilol is rapidly and completely absorbed in the 
gastrointestinal tract. Its elimination half-life is approximately 6 hours.   
It is given as oral dosage form in the treatment of angina pectoris and the management 
of hypertension. Its short biological half-life 6 hrs and frequent administration (usually 
two times a day) make it a potential candidate for sustained release preparations. The 
bioavailability of Carvedilol is approximately 25-35%. Because of such 
pharmacokinetic characteristic the conventional dosage forms of the drug suffer the 
drawbacks of typical immediate release tablets. To overcome these drawbacks, 
sustained release tablets can be prepared. 
 In the present work efforts have been made to develop bilayer sustain release 
matrix tablet of Carvedilol, containing a fast releasing layer of Carvedilol prepared by 
wet granulation technique using sodium starch glycholate as a super disintegrant and a 
sustained releasing layer of Carvedilol prepared by wet granulation method using 
Eudragit RSPO, Ethyl Cellulose and HPMC 4000 in different ratios as sustaining 
polymers. 
Prepared tablets were subjected to various evaluation parameters such as 
hardness, weight variation, % friability, thickness, disintegration, drug content, invitro 
drug release profile.
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9.2.CONCLUSION: 
The results of the experimental study confirm that the polymer concentration 
significantly influence the drug release. The tablets of optimized formulation F3 
containing HPMC 4000 shown 92.94 % drug release at the end of 12 hrs, this 
indicates that it can sustain the drug release till the desired time period. While the 
release rate of the marketed tablet was found to be 95.94%. 
Results discussed above showed that the tablet of all formulations has 
acceptable physical parameters. The in vitro release of all the formulations which 
was subjected to pharmacokinetic data analysis and found that formulations F3 
follows Fickian’s model as the best fitted model to the release profile of the 
formulations. 
• Formulations F3 are found to be stable at accelerated stability as per the 
ICH guidelines for a period of 90 days. 
Finally it can be concluded that with limited number of experiments an 
optimized formulation with desired drug release can be developed with appropriate 
experimental design and optimization technique.    
Future scope of this study 
Since the release rate of the marketed tablet and the optimized bilayer tablet 
is nearly equal and hence the work can be further extended to perform in vivo – in 
vitro correlation. 
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